Welcome to Pharma Unlimited, by Wolters Kluwer. Join host Bertrand Bodson as we go under the microscope to examine some of the biggest issues facing the pharma sector. What will the arrival of Big Tech mean for innovation, risk, and regulation? How will the industry develop new treatments in a post-pandemic world? This five-part series will feature some of the leading lights in life sciences and technology and explore some of the biggest questions facing the pharma industry.
All content for Pharma Unlimited is the property of Wolters Kluwer and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Welcome to Pharma Unlimited, by Wolters Kluwer. Join host Bertrand Bodson as we go under the microscope to examine some of the biggest issues facing the pharma sector. What will the arrival of Big Tech mean for innovation, risk, and regulation? How will the industry develop new treatments in a post-pandemic world? This five-part series will feature some of the leading lights in life sciences and technology and explore some of the biggest questions facing the pharma industry.
Does the pharma industry need to re-evaluate the role it plays in tacking the big issues of our time? The topic is up for debate in the next episode of the Pharma Unlimited podcast, where Michelle Nunn, President & CEO at CARE joins Pharma Unlimited podcast host Bertrand Bodson.
Pharma Unlimited
Welcome to Pharma Unlimited, by Wolters Kluwer. Join host Bertrand Bodson as we go under the microscope to examine some of the biggest issues facing the pharma sector. What will the arrival of Big Tech mean for innovation, risk, and regulation? How will the industry develop new treatments in a post-pandemic world? This five-part series will feature some of the leading lights in life sciences and technology and explore some of the biggest questions facing the pharma industry.
